Jan 15 (Reuters) - Teva Pharmaceutical Industries Ltd :
* TEVA ANNOUNCES U.S. FDA APPROVAL OF TRISENOX® (ARSENIC TRIOXIDE) INJECTION FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
* TEVA PHARMACEUTICAL-‍APPROVAL BASED ON REVIEW BY FDA ON DATA FROM PUBLISHED SCIENTIFIC LITERATURE AND CO‘S GLOBAL SAFETY DATABASE FOR ARSENIC TRIOXIDE​ Source text for Eikon: Further company coverage:
 